MRI and MS diagnosis
Written by Lila Levinson, PhD | Last updated Feb. 27, 2026 Fact-checked by Inês Martins, PhD Magnetic resonance imaging (MRI), which produces detailed…
EBV can trick the immune system to attack myelin in at-risk individuals
Study shows how a common virus and genetic risk factors interact to trigger MS Written by Marisa Wexler, MS | January 15, 2026…
Stuart Schlossman
What is Acthar Gel (repository corticotropin injection)
Acthar Gel is indicated for: Understand more about Acthar Gel, by clicking here…
Stuart Schlossman
What is Purified Cortrophin Gel?
Purified Cortrophin Gel is a prescription medicine that is injected under the skin or into the muscle. It is used…
Stuart Schlossman
Octave wins grant to develop blood test for measuring MS progression
Funding from Valhalla Foundation will advance objective disease assessment by Andrea Lobo, PhD | October 10, 2025 A new grant from the Valhalla Foundation will…
Stuart Schlossman
video: Moderated & Public Q&A with MS Neurologists Boster and LaGanke
Event date: July 26, 2025 Moderator: Stuart Schlossman, President of MS Views and News / MS Patient Advocate At the…
Stuart Schlossman
What is a Multiple Sclerosis Pseudo-exacerbation?
Click the video box to watch this very well presented program Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews…
Stuart Schlossman
Understanding more about MS relapse, MRI’s and Biomarkers for Multiple Sclerosis
Click to Subscribe for the MS Beacon eNewsletter, resources and MS education Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews…
Stuart Schlossman
MS Relapse: 6 Things to Do During a Flare-Up
Multiple sclerosis (MS) can be unpredictable. About 85 percent of people with MS are diagnosed with relapsing-remitting MS (RRMS), which is characterized…
Stuart Schlossman
New Data for Genentech’s Ocrevus (ocrelizumab) Reinforce Significant Benefit on Slowing Disease Progression in Relapsing and Primary Progressive Multiple Sclerosis
April 16, 2021 01:00 ET | Source: F. Hoffmann-La Roche Ltd 85% of treatment-naïve, early-stage relapsing-remitting multiple sclerosis (RRMS) patients achieved no…
Stuart Schlossman
